Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Hyaluronidase Market size was valued at USD 1.07 billion in 2024 and is expected to reach USD 3.13 billion by 2037, registering around 8.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of hyaluronidase is assessed at USD 1.15 billion.
The growth of this market can be attributed to the account of the increasing prevalence of chronic diseases worldwide. Chronic diseases such as cancer and diabetes can lead to the accumulation of hyaluronic acid in tissues. This can cause a variety of problems, such as pain, inflammation, and swelling. Hyaluronidase can be used to break down hyaluronic acid and retrieve these symptoms. Every year 41 million people die out of chronic disease which is 74% of world’s population.
Furthermore, increasing technological advancement in the development of hyaluronidase power injections has made them more effective and safer. For instance, the development of recombinant hyaluronidase has reduced the risk of allergic reactions.
Hyaluronidase Sector: Growth Drivers and Challenges
Growth Drivers
- Escalating Demand for Regenerative Medicines – Regenerative medicine is a field that focuses on the repair and replacement of damaged tissues and organs. Hyaluronidase power injections can be used to prepare cells and tissues for transplantation and to improve the delivery of therapeutic drugs.
- Growing Government Support for Research and Development – Government all across the globe are expanding their support and encouraging research and development in the field of hyaluronidase. This further is leading to the development of new and innovative applications for this technology.
Challenges
- Competition from Other Minimally Invasive Procedures – Hyaluronidase power injections face competition from other minimally invasive procedures, such as botulinum toxin injections and laser treatments. These procedures may be more affordable and have fewer side effects than hyaluronidase power injections. Therefore, it is expected to limit the market expansion of hyaluronidase in the forecast timeframe.
- Lack of Awareness about Hyaluronidase is estimated to Restrict its Market Growth in the Upcoming Period.
- Side Effects Associated with Hyaluronidase is Predicted to Hamper the Market Expansion in the Predicted Period.
Hyaluronidase Market: Key Insights
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~9% |
|
Base Year Market Size |
~USD 1 billion |
|
Forecast Year Market Size |
~USD 12 billion |
|
Regional Scope |
|
Hyaluronidase Segmentation
Source (Animal-Derived Hyaluronidase, Synthetic Hyaluronidase, Bio-Engineered Hyaluronidase)
In terms of source, the animal derived hyaluronidase segment in the hyaluronidase market is estimated to hold the largest market share of 40% by the end of 2037. Most recognized products on the market now use hyaluronidase derived from animals, which has gained widespread acceptance. Currently, producers can create animal-derived hyaluronidase at a lower cost than synthetic or bioengineered hyaluronidase. However, the acceptance of alternate sources is soon anticipated to rise because to the increasing animal rights issues and initiatives. The most popular animal sources are bovine and porcine, which profited from the numerous regulatory licenses they have obtained from organizations like the FDA in the US.
Application (Dermatology, Chemotherapy, Ophthalmology, Plastic Surgery, Cosmetology)
Based on application, the dermatology segment is estimated to grow notably during the time period between 2024-2036. The need for hyaluronidase power injections in the dermatology industry has expanded because of the rising public demand for non-invasive methods to treat skin rashes, dehydration, redness reduction, fine lines, and aging. The rising rates of skin conditions and their consequences will both have a significant beneficial impact on the dermatological market. Skin problem is one of significant health concern affecting 30-60% of population in Europe, recorded as per a study.
Our in-depth analysis of the global market includes the following segments:
|
Source |
|
|
Application |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportHyaluronidase Landscape: Regional Synopsis
North America Market Forecast:
North America industry is estimated to dominate majority revenue share of 33% by 2037, due to increasing number of vendors in the region. The market in this area is anticipated to benefit from the increasing number of vendors offering dermatology and cosmetic treatments such as facial injectables with hyaluronidase power injections. The demand for these items has surged in the area as a result of the government regulators in the area approving a number of hyaluronidase items for use by the populace.
Asia Pacific Market Statistics
In Asia Pacific region, the hyaluronidase market is predicted to grow significantly during the time period between 2025-2037. The primary factor influencing the anticipated expansion in the market for hyaluronidase in the region is the expanding medical tourism sector. India from the APAC region was ranked 10th in the Medical Tourism Index out of 46 countries. The need for hyaluronidase power injections in this area is anticipated to rise as a result of the region's abundance of suppliers that offer the products at lower prices than those in other locations and its less expensive facilities.
Companies Dominating the Hyaluronidase Landscape
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- PrimaPharm Inc.
- Valeant Pharmaceuticals
- Halozyme Therapeutics
- CooperSurgical Fertility Companies
- Amphastar Pharmaceuticals Inc.
- Shreya Life Science
- Bausch & Lomb Incorporated
- Stemcell Technologies Inc.
- Anika Therapeutics Inc.
- Alteogen Inc.
In the News
- Alteogen Inc., a South Korean biotechnology company, announced that the recently completed Tergase clinical trial showed no cases of ADA, including neutralizing antibodies. Tergase is Alteogen's first proprietary product currently undergoing the pharmaceutical approval process by the Korean Ministry of Food and Drug Safety. Tergase is a stand-alone hyaluronidase product that can be used to treat various medical conditions, such as pain relief, edema treatment, and hyaluronic acid filler removal. In particular, compared to animal-derived hyaluronidase products available on the market, this is a high quality, highly pure product with very few impurities and has excellent few side effects. As a new recombinant human hyaluronidase, Alteogen hopes Tergase can be applied to new indications not currently available for existing animal-derived products.
- Halozyme Therapeutics, Inc. announced in June 2023 that argenx received approval from the U.S. Food and Drug Administration (FDA) for VYVGART Hytrulo Injection with ENHANZE for subcutaneous use in the treatment of generalized myasthenia gravis in Adult patients positive for anti-acetylcholine receptor antibodies.
Author Credits: Radhika Pawar
- Report ID: 5293
- Published Date: Jan 03, 2025
- Report Format: PDF, PPT
